Association Between PTK7 Expression and Real-World Survival in Pretreated Patients With EGFR-Wild-Type Lung Adenocarcinoma

IASLC WCLC 2026

Aug 19, 2026
Oncology
Presentation

G.K. Dy, A. Dowlati, M.M. Mirsky, C.S. Baik, L. Deng, D. Delgado, L. Langouche, K.S. Keegan, D. Dornan, A.B. Pai, M. Dugan, D.J. Lennon, A.E. Lisberg

Introduction
Protein tyrosine kinase 7 (PTK7), a pseudokinase involved in embryogenesis, is downregulated in adult tissues but aberrantly overexpressed in various tumor types. In some tumor types, PTK7 overexpression is associated with metastasis, chemoresistance, and poor prognosis. Previous research demonstrated high PTK7 expression in non-small cell lung cancer (NSCLC) samples across histologic subtypes and disease stages, and irrespective of epidermal growth factor receptor (EGFR) mutation status, supporting PTK7 as a promising therapeutic target in lung cancer (Matulonis et al. AACR-NCI-EORTC 2025, Poster C040). This study assessed the prognostic association between PTK7 expression and real-world overall survival (rwOS) in patients with pretreated EGFR-wild-type lung adenocarcinoma.

 

Methods
rwOS by PTK7 expression in tumor samples from patients with EGFR-wild-type lung adenocarcinoma previously treated with chemoimmunotherapy, prior to the start of second- or later-line (2L+) therapy was analyzed in a real-world database (Tempus AI, Inc.). PTK7 expression was quantified by log2(transcripts per million [TPM]+1) and expression was stratified into tertiles to compare outcomes by low versus moderate/high PTK7 expression. The association between PTK7 expression and rwOS was analyzed using a Cox proportional hazards model, adjusted for prognostic factors using multivariable regression. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported.

 

Results
Across tumor samples from 239 patients, the median PTK7 expression (log2 [TPM+1]) was 6.42. Median rwOS was longer in patients with moderate/high PTK7 expression of ≥6.03 (n=158) versus low PTK7 expression of <6.03 (n=81; 14.6 vs 10.9 months; P=0.020). In a multivariable analysis adjusting for age, tumor biopsy site, ECOG performance status, line of therapy, actionable genetic alterations, and PD-L1 expression, PTK7 expression was no longer significantly associated with rwOS (P=0.18). Variables that were independently associated with worse outcomes were later line of therapy (3L vs 2L: HR 1.92, 95% CI 1.24-2.96, P=0.003; and 4+ line vs 2L: HR 1.71, 95% CI 1.02-2.89. P=0.043) and ECOG performance status (ECOG performance status 2+ vs 0: HR 2.56, 95% CI 1.18-5.56; P=0.017), consistent with prior treatment exposure and the advanced disease setting.

 

Conclusions
In this real‑world analysis of 2L+ EGFR-wild‑type lung adenocarcinoma patients previously treated with chemoimmunotherapy, a trend toward differences in rwOS was observed between low and high PTK7 expression groups. However, ECOG performance status and extent of prior therapy emerged as stronger prognostic factors for rwOS than PTK7 expression alone. Ongoing analyses aim to further characterize the low‑PTK7-expressing population, including evaluation of differential gene expression, smoking status, sex, and baseline brain metastases, to better understand drivers of outcomes in this subgroup. The relationship between PTK7 expression and survival will also be explored in the EGFR‑mutant population. HWK‑007, a novel PTK7‑directed antibody-drug conjugate, is currently being evaluated in a phase 1 clinical trial in patients with solid tumors, including non‑squamous EGFR-wild‑type NSCLC (NCT07444814).